Who Paid My Doc
Peter McCullough
Cardiovascular Disease Dallas, TX Medical Doctor
NPI 1386604700 CMS profile 335114
3409 Worth St Ste 500, Dallas, TX 75246
General payments
$663,775
Research payments
$5,700
Ownership & investment interest
$0
Research they led as principal investigator
$469,217
Through program year 2025, Peter McCullough of Dallas, TX is reported in the CMS Open Payments database as having received $663,775 across 679 general payments and $5,700 in research payments paid to them. Separately, studies naming them as principal investigator received $469,217 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21 | 1 | |
| 2024 | General | $425 | 25 | |
| 2023 | General | $3,239 | 42 | |
| 2022 | General | $20,802 | 50 | |
| 2021 | General | $93,178 | 84 | |
| 2020 | General | $183,831 | 136 | |
| 2020 | Research | $5,700 | 4 | |
| 2019 | General | $362,280 | 341 |
Beside peers
- Peter McCullough
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Peter McCullough were reported at $21. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Peter McCullough | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $362,280 | $450 | $127–$1,392 | $163 |
| 2020 | $183,831 | $242 | $77–$751 | $114 |
| 2021 | $93,178 | $335 | $101–$1,037 | $132 |
| 2022 | $20,802 | $395 | $121–$1,211 | $149 |
| 2023 | $3,239 | $443 | $136–$1,283 | $160 |
| 2024 | $425 | $450 | $136–$1,323 | $164 |
| 2025 | $21 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 28 drugsPart D claims
835
Drug cost
$194,577
Branded share of claims
21.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 26 | $43,648 | |
| Verquvo Vericiguat | Brand | 29 | $30,478 | |
| Repatha Sureclick Evolocumab | Brand | 24 | $26,283 | |
| Jardiance Empagliflozin | Brand | 18 | $19,482 | |
| Farxiga Dapagliflozin Propanediol | Brand | 23 | $17,550 | |
| Eliquis Apixaban | Brand | 13 | $16,696 | |
| Repatha Pushtronex Evolocumab | Brand | 13 | $13,605 | |
| Mounjaro Tirzepatide | Brand | 13 | $11,922 | |
| Colchicine | Generic | 56 | $3,289 | |
| Ezetimibe | Generic | 83 | $2,537 |
The 10 drugs with the highest cost, of 28 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 18 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VERQUVO |
|
$161 | 29 | — |
| Azstarys |
|
$47 | — | — |
| Korlym |
|
$33 | — | — |
| Kerendia |
|
$20 | — | — |
| Wegovy |
|
$20 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 18 in the dashboard with a free accountRecords
683 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Texas
Ramin Farzaneh-Far
Cardiovascular Disease · Dallas, TX
John Osborne
Cardiovascular Disease · Grapevine, TX
Darren McGuire
Cardiovascular Disease · Dallas, TX
Ann Navar
Cardiovascular Disease · Dallas, TX
Biykem Bozkurt
Cardiovascular Disease · Houston, TX
Milton Packer
Cardiovascular Disease · Dallas, TX
Related records
Cardiovascular Disease in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.